Mr. Qiu Jiwan (裘霁宛) is the founder of our Group. He was appointed as our Director on June 5, 2015 and was re-designated as our executive Director on March 23, 2023. Mr. Qiu has been serving as our chief executive officer since June 2015, the general manager since September 2021 and the chairman of our Board since February 2022. He is primarily responsible for the strategic planning, business direction and operational management of our Group.

Mr. Qiu also holds various directorships and management positions in our Group companies, including (i) the executive director of Saifu Juli since July 2018, where he has been primarily responsible for the overall management of Saifu Juli; and (ii) the general manager of Cellularforce from August 2018 to March 2023, where he was primarily responsible for the overall management of Cellularforce.

As an industry veteran, Mr. Qiu has nearly 30 years of experience in the biotechnology and pharmaceutical industries, where he started as a biotechnology specialist, gradually extended his role as a leader supervising the discovery, technology and manufacturing platform and accumulated management experience in the R&D and manufacturing of biotech companies, and eventually became a serial entrepreneur with various entrepreneurial achievements. From July 1993 to January 2004, Mr. Qiu served at Hangzhou Jiuyuan Gene Engineering Co., Ltd. (杭州九源基因工程有限公司), a biotech company primarily engaged in the production of injections and active pharmaceutical ingredients (APIs), with his last position being a director of research institute, where he was primarily responsible for new drug development. From February 2004 to June 2005, Mr. Qiu served as a deputy general manager at Epitomics (Hangzhou) Biotechnology Co., Ltd. (宜康(杭州)生物技术有限公司) (“Hangzhou Epitomics”), a biotech company primarily engaged in the R&D and manufacturing of antibody reagents, where he was primarily responsible for the establishment of the production and technology platform. From December 2005 to January 2015, Mr. Qiu founded Jiangsu T-mab BioPharma Co., Ltd. (江苏泰康生物医药有限公司) (“Jiangsu T-mab”) and its two subsidiaries,Hangzhou Genewave Biotechnology Co., Ltd. (杭州基伟生物技术有限公司) (“Hangzhou Genewave”) and Taizhou Beijin Biotechnology Co., Ltd. (泰州贝今生物技术有限公司) (“Taizhou Beijin”), all being companies principally engaged in the R&D and production of genetically engineered drugs, where Mr. Qiu served as (i) the general manager at Hangzhou Genewave beginning from December 2005; (ii) the general manager at Taizhou Beijin beginning from June 2007; and (iii) the general manager at Jiangsu T-mab from July 2008 to January 2015, primarily responsible for their overall operations and management.

Mr. Qiu graduated from Fudan University (复旦大学) in the PRC in July 1993 with a bachelor’s degree in genetics and genetic engineering. He also obtained a master’s degree in business administration (MBA) from Zhejiang University (浙江大学) in the PRC in June 2005.Mr. Qiu was awarded the Third Prize of Zhejiang Province Science and Technology Award (浙江省科学技术三等奖) by the People’s Government of Zhejiang Province (浙江省人民政府) in 2005 and the Second Prize of Hangzhou Science and Technology Progress Award (杭州市科技进步二等奖) by Hangzhou Municipal People’s Government (杭州市人民政府) in February 2006.